Immune cells: plastic players along colorectal cancer progression
暂无分享,去创建一个
[1] Bhanu P. Jena,et al. Journal of Cellular and Molecular Medicine , 2014, Journal of Cellular and Molecular Medicine.
[2] Fabio Grizzi,et al. Prognostic value of innate and adaptive immunity in colorectal cancer. , 2013, World journal of gastroenterology.
[3] Reiko Nishihara,et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. , 2012, The New England journal of medicine.
[4] F. Marincola,et al. Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.
[5] R. Ali,et al. Aspirin as adjuvant therapy for colorectal cancer—reinterpreting paradigms , 2012, Nature Reviews Clinical Oncology.
[6] Douglas G Altman,et al. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration , 2012, BMC Medicine.
[7] H. Ueno,et al. Optimal colorectal cancer staging criteria in TNM classification. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Thun,et al. The role of aspirin in cancer prevention , 2012, Nature Reviews Clinical Oncology.
[9] P. Rothwell,et al. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. , 2012, The Lancet. Oncology.
[10] S. Waldman,et al. Molecular staging individualizing cancer management , 2012, Journal of surgical oncology.
[11] C. Sautès-Fridman,et al. The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.
[12] Axel Benner,et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. , 2011, Cancer research.
[13] G. Kroemer,et al. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. , 2011, Cancer research.
[14] Maureen A. Smith,et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] G. Dranoff,et al. Cancer immunology—analysis of host and tumor factors for personalized medicine , 2011, Nature Reviews Clinical Oncology.
[16] R. Labianca,et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. , 2011, Journal of the National Cancer Institute.
[17] R. Palmqvist,et al. Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor , 2011, Modern Pathology.
[18] R. Schreiber,et al. Natural innate and adaptive immunity to cancer. , 2011, Annual review of immunology.
[19] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[20] Laurence Zitvogel,et al. Immune parameters affecting the efficacy of chemotherapeutic regimens , 2011, Nature Reviews Clinical Oncology.
[21] E. Giovannucci,et al. Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. , 2011, Gastroenterology.
[22] Zlatko Trajanoski,et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Charles Chan,et al. Clinicopathological staging of colorectal cancer: Evolution and consensus—an Australian perspective , 2011, Journal of gastroenterology and hepatology.
[24] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[25] Shuji Ogino,et al. Tumour‐infiltrating T‐cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review , 2010, The Journal of pathology.
[26] C. Garlanda,et al. The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker , 2010, Journal of Translational Medicine.
[27] R. Labianca,et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Michael Karin,et al. Inflammation and colon cancer. , 2010, Gastroenterology.
[29] A. Lièvre,et al. Oncogenic mutations as predictive factors in colorectal cancer , 2010, Oncogene.
[30] M. Karin,et al. Immunity, Inflammation, and Cancer , 2010, Cell.
[31] J. Pignon,et al. Immunogenic death of colon cancer cells treated with oxaliplatin , 2010, Oncogene.
[32] Jun Hee Lee,et al. Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression , 2010, Cell.
[33] M. Karin,et al. Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. , 2010, Cancer cell.
[34] Zlatko Trajanoski,et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Hua Yu,et al. STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.
[36] Mari Mino-Kenudson,et al. Lymphocytic Reaction to Colorectal Cancer Is Associated with Longer Survival, Independent of Lymph Node Count, Microsatellite Instability, and CpG Island Methylator Phenotype , 2009, Clinical Cancer Research.
[37] V. Torri,et al. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. , 2009, The Lancet. Oncology.
[38] P. Kosmidis,et al. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. , 2009, Anticancer research.
[39] M. Omata,et al. Constitutive NF-κB Activation in Colorectal Carcinoma Plays a Key Role in Angiogenesis, Promoting Tumor Growth , 2009, Clinical Cancer Research.
[40] B. Aggarwal,et al. Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe , 2009, Clinical Cancer Research.
[41] N. Zeps,et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] P. Allavena,et al. Cancer-related inflammation , 2008, Nature.
[43] M. Neurath,et al. Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies , 2008, Expert review of anticancer therapy.
[44] F. Marincola,et al. Tumour immunity: effector response to tumour and role of the microenvironment , 2008, The Lancet.
[45] B. Iacopetta,et al. Tumor-Infiltrating Lymphocytes and Perforation in Colon Cancer Predict Positive Response to 5-Fluorouracil Chemotherapy , 2008, Clinical Cancer Research.
[46] Lloyd J. Old,et al. Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.
[47] L. Zitvogel,et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy , 2007, Immunological reviews.
[48] T. Godfrey,et al. Is occult lymph node disease in colorectal cancer patients clinically significant? A review of the relevant literature. , 2007, The Journal of molecular diagnostics : JMD.
[49] Georgia Salanti,et al. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. , 2007, The Lancet. Oncology.
[50] Laurence Zitvogel,et al. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.
[51] V. Torri,et al. Reduced Likelihood of Metastases in Patients with Microsatellite-Unstable Colorectal Cancer , 2007, Clinical Cancer Research.
[52] M. Neurath,et al. The T-box transcription factor eomesodermin controls CD8 T cell activity and lymph node metastasis in human colorectal cancer , 2007, Gut.
[53] P. Rothwell,et al. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies , 2007, The Lancet.
[54] M. Koch,et al. Tumor Infiltrating T Lymphocytes in Colorectal Cancer: Tumor-Selective Activation and Cytotoxic Activity In Situ , 2006, Annals of surgery.
[55] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[56] D. Parkin,et al. The global health burden of infection‐associated cancers in the year 2002 , 2006, International journal of cancer.
[57] K R Abrams,et al. Meta‐analysis: colorectal and small bowel cancer risk in patients with Crohn's disease , 2006, Alimentary pharmacology & therapeutics.
[58] J. Beebe-Dimmer,et al. Chronic Inflammation: A Common and Important Factor in the Pathogenesis of Neoplasia , 2006, CA: a cancer journal for clinicians.
[59] Z. Trajanoski,et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.
[60] C. Boland,et al. Serrated Adenomas Have a Pattern of Genetic Alterations That Distinguishes Them from Other Colorectal Polyps , 2005, Cancer Epidemiology Biomarkers & Prevention.
[61] M. Caraglia,et al. Dendritic Cell-Mediated Cross-Presentation of Antigens Derived from Colon Carcinoma Cells Exposed to a Highly Cytotoxic Multidrug Regimen with Gemcitabine, Oxaliplatin, 5-Fluorouracil, and Leucovorin, Elicits a Powerful Human Antigen-Specific CTL Response with Antitumor Activity in Vitro1 , 2005, The Journal of Immunology.
[62] B. Robinson,et al. Immunotherapy and chemotherapy — a practical partnership , 2005, Nature Reviews Cancer.
[63] C. Ko,et al. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. , 2005, Journal of the National Cancer Institute.
[64] Hans Clevers,et al. At the Crossroads of Inflammation and Cancer , 2004, Cell.
[65] C. Ostwald,et al. Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. , 2004, Human pathology.
[66] G. Beck,et al. A randomized trial of aspirin to prevent colorectal adenomas. , 2003, The New England journal of medicine.
[67] R. MacKie,et al. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. , 2003, The New England journal of medicine.
[68] R. Schreiber,et al. Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.
[69] C. Begg,et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] K. Abrams,et al. The risk of colorectal cancer in ulcerative colitis: a meta-analysis , 2001, Gut.
[71] H. Adami,et al. Infections as a major preventable cause of human cancer , 2000, Journal of internal medicine.
[72] S. Bull,et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. , 2000, The New England journal of medicine.
[73] C. Ratto,et al. Accurate lymph-node detection in colorectal specimens resected for cancer is of prognostic significance , 1999, Diseases of the colon and rectum.
[74] H Nagura,et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.
[75] Per Capita,et al. About the authors , 1995, Machine Vision and Applications.
[76] A R Feinstein,et al. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. , 1985, The New England journal of medicine.
[77] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[78] M. Kloor,et al. The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. , 2009, Cancer immunity.
[79] P. Loehrer. Long-term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs and Risk of Colorectal Cancer , 2007 .
[80] R. Blumberg,et al. The immunology of mucosal models of inflammation. , 2002, Annual review of immunology.
[81] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[82] L. Old,et al. IMMUNOLOGY OF EXPERIMENTAL TUMORS. , 1964, Annual review of medicine.
[83] Old Lj,et al. Immunology of Experimental Tumors , 1964 .